RATIONALE: During the pathogenesis of PD, monomeric a-synuclein assembles into higherordered structures that ultimately become pathologic and drive neuronal cell death. Pathologic a-synuclein can spread from cell to cell, contributing to the progressive pathogenesis of PD. What drives the abnormal assembly of pathologic a-synuclein and the cell injury and death mechanisms that are activated by pathologic a-synuclein are not known.
RESULTS: Recombinant a-synuclein preformed fibrils (PFFs), which are similar in structure to those found in PD, were used to model pathologic a-synuclein both in vitro and in vivo. We investigated the cellular cell death pathways that contribute to and drive a-synuclein PFF-mediated neuronal cell death. Pathologic a-synuclein was found to activate nitric oxide synthase (NOS), causing DNA damage and poly(adenosine 5′-diphosphate-ribose) polymerase-1 (PARP-1) activation, leading to cell death via parthanatos. a-Synuclein PFF was found to primarily kill neurons via parthanatos, because necroptosis and autophagy inhibition had no effect on a-synuclein PFF neurotoxicity and there was only modest protection by caspase inhibition. Neuron-toneuron transmission of pathologic a-synuclein and accompanying pathology and neurotoxicity in primary neuronal cultures were completely attenuated by clinically available PARP inhibitors or by deletion of PARP-1. a-Synuclein PFF-induced loss of DA neurons and biochemical and behavioral deficits in vivo were significantly prevented by PARP inhibition or lack of PARP-1. PAR generated by PARP-1 activation also binds to a-synuclein, accelerating its fibrillization and converting pathologic a-synuclein to a more misfolded compact strain with 25-fold enhanced toxicity. PAR-modified a-synuclein PFF-injected mice showed accelerated disease progression and phenotype compared to a-synuclein PFFinjected mice. Moreover, PAR levels were increased in the cerebrospinal fluid (CSF) in two independent patient cohorts and brains of PD patients, providing evidence that parthanatos may contribute to the pathogenesis of PD.
CONCLUSION:
We identified PARP-1 activation and the generation of PAR as a key mediator of pathologic a-synuclein toxicity and transmission. Activation of parthanatos is the primary driver of pathologic a-synuclein neurodegeneration. Inhibition of PARP and depletion of PARP-1 substantially reduces the pathology induced by the transmission of pathologic asynuclein. In a feed-forward loop, PAR converted pathologic a-synuclein to a more toxic strain and accelerated neurotoxicity both in vitro and in vivo. Consistent with the notion that PARP-1 activation plays a role in PD pathogenesis, PAR levels were increased in the CSF and brains of PD patients. Thus, strategies aimed at inhibiting PARP-1 activation could hold promise as a disease-modifying therapy to prevent the loss of DA neurons in PD and related a-synucleinopathies. Moreover, assessment of PAR levels in the CSF could serve as a theranostic biomarker for diseasemodifying therapies in these disorders.
P
arkinson's disease (PD) is an age-related neurodegenerative disease in which asynuclein (a-syn) deposits as fibrils in intracytoplasmic inclusions in structures termed Lewy bodies and neurites (1) . Recombinant a-syn can be aggregated in vitro to form fibrils similar in structure to those found in vivo (2) , and these a-syn preformed fibrils (a-syn PFFs) can spread in a prion-like manner: both in in vitro neuronal cultures and in vivo when injected into the mouse brain with accompanying phosphorylation of a-syn on serine-129, a marker of pathologic a-syn (3) and neurotoxicity (2, 4, 5) . Although it is clear that aggregated a-syn underlies the pathology of PD, what drives abnormal aggregation of a-syn and the cell injury and death mechanisms that are activated by this aggregation are not yet known. Because poly(adenosine 5′-diphosphate-ribose) (PAR) polymerase-1 (PARP-1) and PAR play a major contributing role in cell death relevant to neurologic disorders (6, 7), here, we evaluated a role for PARP-1 and PAR in pathologic a-syn-induced neurodegeneration.
a-Syn PFF-induced neurotoxicity is PARP-1 dependent
To determine whether a-syn PFF induces the activation of PARP, levels of PAR were measured using a highly sensitive and specific PAR monoclonal antibody after administration of a-syn PFF to primary mouse cortical neurons (Fig. 1) . a-Syn PFF (1 mg/ml) induced PARP activation peaks between 3 and 7 days and remained elevated for up to 14 days (Fig. 1A) . The elevation of PAR was accompanied by neuron death as assessed by propidium iodide (PI) staining (Fig. 1, B and C). Treatment of cortical neurons with 1 mM of the PARP inhibitors [ABT-888 (veliparib), AG-014699 (rucaparib), or BMN 673 (talazoparib)] prevented the a-syn PFF-mediated PARP activation and cell death (Fig. 1, B to D S1, A and  B) . These PARP inhibitors prevented a-syn PFFinduced cell death and PARP activation at concentrations as low as 10 nM (fig. S1, C to E). They also reduced a-syn PFF-mediated phosphorylation of a-syn at serine-129 (p-a-syn) ( fig. S1 , F and G) and a-syn aggregation ( fig. S1 , H and I), both of which are associated with pathology in a-synucleinopathies (4). Because PARP-1 plays a major role in parthanatos (9, 10), we deleted PARP-1 from cortical neurons using CRISPR-Cas9 via adeno-associated virus (AAV) transduction carrying a guide RNA against PARP-1 ( The necroptosis inhibitor necrostatin-1 (Nec-1) and the autophagy inhibitor 3-methyladenine (3-MA) had no effect, whereas the PARP inhibitor ABT-888 prevented a-syn PFF toxicity ( fig. S2 , G to M). Because PARP inhibition and knockout of PARP-1 reduced the accumulation of pathologic a-syn as indicated by a reduction of p-a-syn immunostaining, we assessed cell-to-cell transmission of a-syn (5). Knockout of PARP-1 or PARP inhibition did not show a difference in the levels of a-syn-biotin PFF in endosomal-enriched fractions ( fig. S3 , A to D) (5), indicating that PARP-1 did not affect the uptake of a-syn PFF. However, knockout of PARP-1 reduced the cell-to-cell transmission of pathologic a-syn by inhibiting propagation of a-syn PFF into recipient cells ( fig. S3 , E to G).
a-Syn PFF activates PARP-1 via nitric oxide-induced DNA damage
To determine how a-syn PFF activates PARP-1, we measured levels of damaged DNA and activation of nitric oxide synthase (NOS) (Fig. 2  and fig. S4 ) (12) (13) (14) . a-Syn PFF treatment increased NO levels in primary cultured neurons, whereas pretreatment with the NOS inhibitor, Nw-nitro-L-arginine methyl ester hydrochloride (L-NAME), prevented a-syn PFF-induced NO generation ( Fig. 2A) . NO levels also increased in a-syn PFF-injected brain (Fig. 2B ). In both a-syn PFF-treated primary cultured neurons and a-syn PFF-injected brain, expression of gH2A.X, a marker of DNA strand breaks (15), was increased (Fig. 2, C to G, and fig. S4A ).
a-Syn PFF resulted in substantial numbers of neurons with DNA damage, whereas no such damage was detected by treatment with L-NAME (Fig. 2, C to E, and fig. S4 , B to D). Consistent with suppression of PARP-1 activation (Fig. 2C) , a-syn PFF-induced cell death was prevented by L-NAME ( fig. S4 , E to G). Thus, a-syn PFF activates NOS, leading to DNA damage and PARP-1 activation. Moreover, a-syn PFF primarily kills neurons through parthanatos, and PARP-1 contributes to generation of pathologic a-syn.
PARP-1 activation mediates a-syn PFF-induced loss of DA neurons
Because synthetic a-syn PFF killed primary cortical neurons via parthanatos, we sought to determine whether parthanatos plays a role in the loss of dopamine (DA) neurons after the intrastriatal injection of a-syn PFF (Fig. 3) (4, 5) . A single intrastriatal injection of a-syn PFF (5 mg) induced PARP activation and increased PAR levels (Fig. 3A) . Intrastriatal injection of a-syn PFF into PARP-1 KO mice failed to increase PAR levels (Fig. 3A) . As previously described (4), a single intrastriatal injection of a-syn PFF leads to an approximate 50% loss of DA neurons 6 months after the injection in wild-type (WT) mice (Fig. 3, B and C) . In contrast, a single intrastriatal injection of a-syn PFF into PARP-1 KO mice failed to induce DA cell loss (Fig. 3 , B and C). WT mice were also fed a diet containing the PARP inhibitor ABT-888 (125 mg/kg) and compared with mice given a control diet (Fig. 3 , B and C). Mice treated with ABT-888 exhibited significantly less loss of DA neurons after an intrastriatal injection of a-syn PFF compared to mice on the control diet (Fig. 3, B and C). ABT-888 also reduced the formation of a-syn PFF-induced increase in PAR levels ( fig. S5A ). Tyrosine hydroxylase (TH) and DA transporter (DAT) levels were also reduced in WT mice in response to a-syn PFF, whereas the reduction in TH and DAT levels was prevented in PARP-1 KO or ABT-888-treated WT mice ( fig. S5 , A to C). The loss of DA neurons was accompanied by a reduction in striatal DA and its metabolites in WT mice, but not PARP-1 KO or ABT-888-treated mice (Fig. 3D and fig. S5 , F to H). As previously described (4, 5) , injection of intrastriatal a-syn PFF leads to a-syn pathology in DA neurons of WT mice (figs. S5, A, D, and E, and S6, A to D). a-Syn pathology was markedly reduced in PARP-1 KO mice and ABT-888-treated WT mice consistent with the absence and reduction of neurodegeneration, respectively. Intrastriatal injection of a-syn PFF caused deficits on the pole test (16), a sensitive behavioral measurement of dopaminergic function, in WT mice, whereas there were no deficits in PARP-1 KO and ABT-888-treated WT mice (Fig. 3E and fig. S6E ). Both forelimb plus hindlimb and forelimb grip strength were also reduced in WT mice after a-syn PFF injection, but not in PARP-1 KO or ABT-888-treated WT mice (Fig. 3F and fig. S6F ). Thus, the striatal a-syn PFF-induced loss of DA neurons is dependent on PARP-1.
PAR accelerates a-syn fibrillization
Because PAR causes liquid demixing of intrinsically disordered proteins leading to their aggregation (17) , experiments were performed to determine whether PAR could seed and accelerate Kam et (H) Quantification of cell death. Bars represent means ± SEM. Two-way ANOVA followed by Tukey's post hoc test (n = 3). *P < 0.05, **P < 0.005, ***P < 0.0005. Bars represent means ± SEM. Two-way ANOVA followed by Tukey's post hoc test (n = 5 to 10 mice per group). (E and F) One hundred eighty days after a-syn PFF injection, the pole test (E) and grip strength test (F) were performed in WT, PARP-1 KO, or WT mice fed with ABT-888. Data are the means ± SEM. Two-way ANOVA followed by Tukey's post hoc test (n = 6 to 8 mice for PARP-1 KO, n = 11 to 30 mice for ABT-888). *P < 0.05, **P < 0.005, ***P < 0.0005. a-syn aggregation. Recombinant a-syn was incubated at 37°C and agitated in the presence and absence of 5 nM PAR, concentrations that are observed in brain tissue (9) . High-molecular weight forms of a-syn in the absence of PAR were observed as early as 4 hours of incubation, and a-syn continued to fibrillize with time ( Fig. 4A ). Different molecular weight forms of a-syn were observed at 72 hours. In the presence of PAR, the fibrillization of a-syn was markedly accelerated with different molecular weight forms of a-syn being observed as early as 24 hours of incubation (Fig. 4A) . PAR accelerated the fibrillization of a-syn as indicated by thioflavin T fluorescence, whereas PAR alone had no effect (Fig. 4B) . PAR caused the fibrillization of a-syn at lower temperatures than required for a-syn fibrillization in the absence of PAR ( fig. S7A ). At 12 hours, a-syn fibrils were observed in the absence of PAR and were fully formed and extensive after 72 hours of agitation and incubation at 37°C (Fig. 4C ). In contrast, in the presence of PAR, a-syn was extensively fibrillated at 12 hours and was more extensively fibrillated at 36 and 72 hours (Fig. 4C) . We monitored the concentration dependence of fibrillization at 36 hours. PAR (1 nM) enhanced a-syn fibrillization, with peak aggregation occurring at 5 nM PAR, whereas 20 nM PAR did not appreciably increase a-syn fibrillization ( fig. S7 , B and C). a-Syn was not PARylated by PARP-1 activity, but it bound to PAR through its N-terminal domain ( fig. S8 , A to C). In the a-syn PFF-injected mouse brain, about 20% of a-syn was PAR bound (fig. S8, D and E). Because PAR is a highly negatively charged molecule, we tested the effects of another highly charged polymer, PolyA. a-Syn failed to interact with polyadenylic acid (PolyA), and it had no effect on a-syn fibrillization (fig. S7, D to F). ADP ribose monomer also failed to interact with a-syn and had no effect on a-syn fibrillization ( fig. S7 , D to F). To determine whether endogenous PAR formation accelerates a-syn fibrillization, primary mouse cortical neurons overexpressing WT human a-syn after AAV-a-syn transduction were treated with a toxic dose of N-methyl-D-aspartate (NMDA). In WT cultures, NMDA treatment ABT-888 (10 mM) or AG-014699 (1 mM) for 1 hour was pretreated for 1 hour. a-Syn fibrillization was detected by Western blot (WB) analysis 6 hours after NMDA treatment. (F) a-Syn PFF or PAR-a-syn PFF was incubated with increasing concentrations of PK (0 to 2.5 mg/ml) and immunoblotted with a-syn antibody (top). Quantification represents the ratio of cleaved to uncleaved a-syn (bottom). Data are means ± SEM. (bottom). Unpaired twotailed Student's t test in each concentration of PK (n = 3). (G) Representative immunostaining and quantification of p-a-syn (red) in primary cortical neurons treated with a-syn PFF or PAR-a-syn PFF for 1, 4, and 7 days. Bars represent means ± SEM. Two-way ANOVA followed by Tukey's post hoc test (n = 3). Scale bar, 20 mm. (H) Primary cortical neurons treated with a-syn PFF or PAR-a-syn PFF were sequentially extracted with 1% Triton X-100 (TX-100) (TX soluble) and 2% SDS (TX insoluble). Lysates were subjected to immunoblotting using a-syn, p-a-syn, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies. Bars represent means ± SEM. Two-way ANOVA followed by Tukey's post hoc test (n = 3). ND, not detected. *P < 0.05, **P < 0.005, ***P < 0.0005. AU, arbitrary units; DAPI, 4′,6-diamidino-2-phenylindole.
activated PARP and led to a concomitant aggregation of a-syn, whereas a-syn did not aggregate in PARP-1 KO cultures treated with NMDA (Fig. 4D ). Exogenous administration of PAR via BioPORTER (9) increased the aggregation of a-syn in both WT and PARP-1 KO cultures transduced with AAV-a-syn ( fig. S9A) . Thus, PAR, not PARP-1, can directly increase a-syn aggregation. Two different PARP inhibitors, ABT-888 and AG-014699, prevented a-syn aggregation and PARP activation in response to NMDA administration (Fig. 4E) . In SH-SY5Y neuroblastoma cells, the potent PARP activator N-methyl-N′-nitro-Nnitrosoguanidine (MNNG) enhanced the aggregation of overexpressed WT or A53T a-syn, whereas MNNG had no effect in PARP-1 KO SH-SY5Y cells ( fig. S9 , B and C). Exogenous administration of PAR increased the aggregation of a-syn in both SH-SY5Y WT and SH-SY5Y PARP-1 KO cultures ( fig. S9D ). Two different PARP inhibitors, ABT-888 and AG-014699, prevented a-syn aggregation and PARP activation in response to MNNG administration in SH-SY5Y cells ( fig. S9E ). Thus, PAR seeds and accelerates a-syn aggregation.
PAR promotes formation of more toxic a-syn PFF strains
To determine whether PAR changes the biophysical properties of a-syn PFF, a series of biochemical analysis were conducted using a-syn PFF and a-syn PFF in the presence of PAR (PAR-a-syn PFF). First, proteinase K (PK) digestion of a-syn PFF was performed and monitored by a-syn immunoblots. a-Syn PFF and PAR-a-syn PFF showed very distinct banding patterns after PK digestion, with PAR-a-syn PFF's being more resistant to increasing concentrations of PK (Fig. 4F ). PAR-a-syn PFF predominantly showed an undigested band of a-syn (first band), with comparable digested bands only at higher concentrations of PK, whereas a-syn PFF degraded into smaller fragments (second to fifth band) at lower concentrations of PK (0.5 and 1 mg/ml), and these bands became predominant at higher concentrations of PK (1.5 to 2.5 mg/ml) (Fig. 4F) . Epitope-specific antibodies to a-syn revealed that PAR rendered the majority of the a-syn regions resistant to PK digestion ( fig. S10A ). The resistance to PK digestion of PAR-a-syn PFF suggests that PAR induces the formation of a distinct a-syn PFF strain with a more misfolded and compact structure than a-syn PFF.
We then compared the a-syn PFF-and PAR-asyn PFF-induced neuronal cell death in cultured neurons. After 14 days of treatment, cell death was enhanced in cultures treated with PAR-asyn PFF as compared to that with a-syn PFF ( fig. S10B ). PAR itself did not cause significant cell death even at a higher concentration (20 nM) ( fig. S10B ). To further confirm the potencies of neuropathology, p-a-syn immunoreactivity was monitored after treatment with varying concentrations of a-syn PFF or PAR-a-syn PFF. P-a-syn immunoreactivity was observed at 20 ng of PAR-a-syn PFF at an equivalent level to 500 ng of a-syn PFF, suggesting that the PAR modification of a-syn PFF increased toxicity by 25-fold ( fig. S10, C and D) . PAR-asyn PFF significantly increased p-a-syn immunoreactivity at higher concentrations (fig. S10, C and D). P-a-syn immunoreactivity at different time points was also monitored in cultured neurons exposed to a-syn PFF or PAR-a-syn PFF. In the absence of PAR, a-syn PFF treatment leads to barely detectable p-a-syn immunoreactivity 1 day after treatment, whereas PAR-a-syn PFF (E) DA concentrations in the striatum of PBS-, a-syn PFF-, PAR-a-syn PFF-, or PAR-injected mice at 1, 3, and 6 months measured by HPLC. Bars represent means ± SEM. Two-way ANOVA followed by Tukey's post hoc test (n = 4 to 6 mice per group). (F and G) Behavioral abnormalities of PBS-, a-syn PFF-, PAR-a-syn PFF-, or PAR-injected mice at 1, 3, and 6 months measured by the pole test (F, n = 9 to 24 mice per group) and the grip strength test (G, n = 6 to 14 mice per group). Data are the means ± SEM. Two-way ANOVA followed by Tukey's post hoc test. *P < 0.05, **P < 0.005, ***P < 0.0005.
treatment leads to detectable levels of p-a-syn immunoreactivity as early as 1 day after treatment and markedly enhances immunoreactivity at 7 days (Fig. 4G ). Aggregated and phosphorylated a-syn were detectable at 4 days, whereas in the absence of PAR, these species of a-syn were only detectable after 7 days of treatment (Fig. 4H ).
In the presence of PAR, there was an increase in the aggregated form of a-syn (Fig. 4H) . We then compared the cell-to-cell transmission of a-syn PFF and PAR-a-syn PFF in neuronal cultures transduced with AAV-a-syn ( fig. S11 ). The exosomal secretion (18) of PAR-induced a-syn oligomers by NMDA treatment was significantly increased in WT neurons, but not in PARP-1 KO neurons or in WT neurons with treatment of a PARP inhibitor ( fig. S11, A and B) . PAR-asyn PFF was enriched in the endosome-enriched fraction, and propagation of pathologic p-a-syn was enhanced in recipient cells as compared to those of a-syn PFF (fig. S11, C to F). Thus, PAR converts pathologic a-syn to a more misfolded compact toxic strain.
PAR-a-syn PFF strain is more neurotoxic in vivo
To determine whether the PAR-a-syn PFF strain exhibits enhanced neurotoxicity in vivo, a single intrastriatal injection of PAR-a-syn PFF (5 mg) was compared to that of a-syn PFF (5 mg). We observed a trend toward the loss of DA neurons ipsilateral to the injection side of SNpc after 1 month and a significant loss of DA neurons 3 months after PAR-a-syn PFF injection, whereas a-syn PFF injection had no effect at these time points (Fig. 5, A and B, and fig. S12A ). Six months after PAR-a-syn PFF or a-syn PFF injection, there was no significant difference in the loss of DA neurons (Fig. 5, A and B, and fig. S12A ). There was no significant loss of DA neuron contralateral to the injection side at any time point ( fig. S12 , B and C). PAR injection by itself had no effect on DA neuron number (Fig. 5, A and B, and fig. S12A ). PAR-a-syn PFF also accelerated the loss of striatal DA and its metabolites, with significant reductions in DA and its metabolites 1 month after the PAR-a-syn PFF injection in contrast to a-syn PFF (Fig. 5E and  fig. S13 ). Three and 6 months after PAR-a-syn PFF or a-syn PFF injection, there was no significant difference in the loss of DA and its metabolites ( Fig. 5E and fig. S13 ). TH and DAT levels were also reduced after PAR-a-syn PFF compared to a-syn PFF 3 months after the injection, whereas there was no difference in the degree of loss at 6 months ( fig. S14, A and B) . a-Syn pathology as assessed by immunostaining for p-a-syn in DA neurons was increased by PAR-a-syn PFF compared to a-syn PFF at 3 and 6 months after injection (Fig. 5, C and D) . PAR-a-syn PFF caused a deficit on the pole test at 3 months consistent with loss of DA neurons and DA deficits at 3 months, whereas there were no significant deficits in a-syn PFF-injected or PAR-injected mice ( Fig. 5F and fig. S14C ). Both forelimb plus hindlimb and forelimb grip strength were also reduced in PAR-a-syn PFFinjected mice but not in a-syn PFF-injected or PAR-injected mice at 3 months (Fig. 5G and  fig. S14D ). At 6 months, there was no significant difference in the behavioral deficits induced by PAR-a-syn PFF or a-syn PFF (Fig. 5, F and G, and fig. S14, C and D). Thus, PAR-a-syn PFF is substantially more neurotoxic than a-syn PFF in vivo.
Increased levels of PAR in the CSF of patients with PD
To determine whether PAR plays a role in patients with PD, PAR levels were monitored in the cerebrospinal fluid (CSF) of patients with PD versus controls (tables S1 and S2) using a sensitive enzyme-linked immunosorbent assay (ELISA) for PAR ( fig. S15A ). PAR levels were elevated in patients with PD compared to controls in two independent patient cohorts (Fig. 6 , A and E). One of the cohorts showed a positive correlation between PAR levels and either disease duration or progression (Fig. 6 , B to D and F to H). As previously reported, PAR levels were increased in the substantia nigra of patients with PD compared to controls ( fig. S15 , B and C, and table S3) (19) .
Discussion
Our results indicate that a-syn PFF kills neurons both in vitro and in vivo via activation of PARP-1 in a cell death process designated parthanatos (20) . Knockout of PARP-1 and inhibition of PARP prevents the neurodegeneration and behavioral deficits initiated by an intrastriatal a-syn PFF injection. Activation of parthanatos seems to be the primary driver of a-syn PFF neurodegeneration because necroptosis and autophagy inhibitors had no effect on a-syn PFF neurotoxicity, and there is only modest protection by caspase inhibition. It is known that a-syn PFFs induce inflammatory mediator activation (21, 22) , which likely contributes, in part, to cell death and accounts for the modest neuroprotection by the broad-spectrum caspase inhibitor Z-VAD. It will be important in future studies to explore the role of caspase activation, neuroinflammation, and neurodegeneration induced by a-syn PFF. For the studies reported here, we used a-syn PFF (5 mg/ml) or PAR-a-syn PFF (5 mg/ml) for the primary neuronal culture experiments, which represents a concentration of about 340 nM in monomeric equivalents. The actual concentration of a-syn PFFs would be lower. Because a-syn is thought to represent about 1% of soluble brain protein (23) , its monomeric concentration is estimated to be in the low micromolar range in the Kam brain. The concentration of higher-order species of a-syn, which is not known, would be lower in the brain. For both the primary neuronal cultures and the intrastriatal injections, 5 mg of a-syn PFF or PAR-a-syn PFF was used for each experiment. Because the concentrations used for these and related studies are within the range of the concentration of monomeric a-syn in the brain, the concentration of a-syn PFF or PAR-a-syn PFF is likely to be within the range of the concentration of higher-order species of a-syn in the brain. Providing some specificity to these experiments is the observation that the concentration of a-syn PFF used here and in other studies has no toxicity in the absence of endogenous a-syn (2, 4). Recent studies have identified conformational variants of a-syn strains that exhibit distinct neurotoxicity, seeding abilities, and propagation, which contribute to different properties of a-synucleinopathies (24, 25) . Given that a-syn PFF induces PARP activation and PAR accumulation, PAR then accelerates a-syn fibrillization and changes the biochemical properties of a-syn PFF, converting it to a more toxic strain. Consistent with this notion, PAR-a-syn PFF shows an approximate 25-fold increase in a-syn aggregation and neurotoxicity compared to the parental a-syn PFF. Moreover, PAR-a-syn PFF-injected mice show an accelerated disease progression and phenotype compared to a-syn PFF-injected mice.
In addition to PAR levels being increased in cultured neurons and mouse brain, PAR levels in PD are elevated in the substantia nigra and in the CSF. The elevation of PAR in the CSF and brains of patients with PD and evidence of PARP activation in the substantia nigra of patients with PD suggest that PARP activation contributes to the pathogenesis of PD through parthanatos and conversion of a-syn to a more toxic strain. In future studies, it will be important to determine whether the increase of PAR in CSF from human PD correlates with disease severity or progression. Moreover, it will be important to determine whether it can serve as a theranostic biomarker for disease-modifying therapies. Because PARP inhibitors are currently being used clinically as synergizing agents in the treatment of cancer (26), they could be considered for disease modification in PD (6).
Materials and methods Animals
C57BL/6 WT and PARP-1 KO mice were obtained from the Jackson Laboratories (Bar Harbor, ME). The littermates of WT and PARP-1 KO mice were used in experiments. All housing, breeding, and procedures were performed according to the NIH Guide for the Care and Use of Experimental Animals and approved by Johns Hopkins University Animal Care and Use Committee.
Preparation of a-syn PFF and PAR-a-syn PFF
Recombinant mouse a-syn proteins were purified as previously described (5) . After purification, bacterial endotoxins were removed using Toxineraser endotoxin removal kit (GeneScript).
a-syn PFF were prepared in PBS by constantly agitating a-syn with a thermomixer (1,000 rpm at 37°C) (Eppendorf, Hamburg, Germany). After 7 days of incubation, the a-syn aggregates were diluted to 0.1 mg/ml with PBS and sonicated for 30 s (0.5 sec pulse on/off) at 10% amplitude (Branson Digital Sonifier, Danbury, CT). Synthesis and purification of PAR polymer were performed as described (27) . PAR-a-syn PFF was prepared by adding 5 nM or indicated dose of PAR in a-syn fibrillization reaction.
Stereotaxic injection of a-syn PFF
Two to 3-month-old WT and PARP-1 KO mice were deeply anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). PBS, a-syn PFF (5 mg), PAR-a-syn PFF (5 mg) or PAR was unilaterally injected into striatum (2 ml per hemisphere at 0.4 ml/min) with the following coordinates: anteroposterior (AP) = +0.2 mm, mediolateral (ML) = + 2.0 mm, dorsoventral (DV) = +2.8 mm from bregma. After the injection, the needle was maintained for an additional 5 min for a complete absorption of the solution. After surgery, animals were monitored and post-surgical care was provided. Behavioral tests were performed 1, 3 and 6 months after injection and mice were euthanized for biochemical and histological analysis. For biochemical studies, tissues were immediately dissected and frozen at -80°C. For histological studies, mice were perfused with PBS and 4% PFA and brains were removed, followed by fixation in 4% PFA overnight and transfer to 30% sucrose for cryoprotection.
Thioflavin T (ThT) binding assay a-syn fibrillization with or without PAR was monitored with ThT fluorescence. Aliquots of 5 ul from the incubation mixture were taken at various time points, diluted to 100 ml with 25 mM ThT in PBS, and incubate for 10 min at room temperature. The fluorescence was recorded at 450 nm excitation and 510 nm emission using SpectraMax plate reader (Molecular Devices, Sunnyvale, CA). The experiments were performed in triplicate.
Transmission electron microscopy (TEM) measurements a-syn PFF or PAR-a-syn PFF were adsorbed to glow discharged 400 meshed carbon coated copper grids (Electron Microscopy Sciences, Hatfield, PA) for 2 min, quickly washed twice with Tris-HCl (50 mM, pH 7.4), and floated upon two drops of 0.75% uranyl formate for 30 s each. The grids were allowed to dry before imaging on a Phillips CM 120 TEM operating at 80 kV. The images were captured and digitized with an ER-80 CCD (8 megapixel) by advanced microscopy techniques.
Intracellular delivery of PAR
Purified PAR was intracellularly delivered using BioPORTER (Genelnatis, San Diego, CA) according to the manufacturer's instructions (9) . PAR polymer was diluted to desired concentration with PBS. The diluted solution was added to the dried BioPORTER reagent and mixed gently, followed by incubation at room temperature for 5 min. The BioPORTER-PAR complex was added to cell culture after a wash in serum-free media and incubated for 3-4 h at 37°C. Cultures were subsequently used for experiments.
Tissue lysate preparation and Western blot analysis
Human post mortem brain (Table S3) or mouse brain tissue were homogenized and prepared in lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton x-100, 0.5% SDS, 0.5% sodium-deoxycholate, phosphatase inhibitor mixture I and II (Sigma-Aldrich, St. Louis, MO), and complete protease inhibitor mixture (Roche, Indianapolis, IN)], using a Diax 900 homogenizer (Sigma-Aldrich). After homogenization, samples were rotated at 4°C for 30 min for complete lysis, the homogenate was centrifuged at 15,000 x g for 20 min and the supernatants were used for further analysis. Protein levels were quantified using the BCA assay (Pierce, Rockford, IL), samples were separated using SDSpolyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were blocked with 5% non-fat milk in TBS-T (Trisbuffered saline with 0.1% Tween-20) for 1 h, probed using primary antibodies (Table S4) and incubated with appropriate HRP-conjugated secondary antibodies (Cell signaling, Danvers, MA). The bands were visualized by ECL substrate.
Immunoprecipitation (IP), overlay, and in vitro ribosylation assay of PAR
The deletion mutants of a-syn-GFP were generated using site-directed mutagenesis (Agilent, Santa Clara, CA) according to the manufacturer's instructions. SH-SY5Y cells were transfected with either a-syn-GFP or its deletion mutants by Polyfect (Qiagen, Hilden, Germany) for 36 h and then further incubated with 50 mM MNNG for 15 min. The cells were washed 2 times with PBS and harvested with lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton x-100, 0.5% SDS, 0.5% sodiumdeoxycholate, phosphatase inhibitor mixture I and II (Sigma-Aldrich), and complete protease inhibitor mixture (Roche)]. The supernatants after centrifugation at 15,000 x g for 20 min were used for measuring the protein concentration by BCA assay. The same amount of proteins were incubated with anti-PAR antibody (Table S4 ) overnight at 4°C, followed by incubation with PureProteome kappa Ig binder magnetic beads (Millipore, Burlington, MA) for 3 h at 4°C. The IP complexes were washed 5 times with IP buffer and then denatured by boiling for 5 min after adding 2x Laemlli Buffer plus b-mercaptoethanol. For the PAR overlay assay, the equal amount of BSA or purified a-syn protein was spotted onto a nitrocellulose membrane. The membranes were washed once with TBS-T buffer and air-dried, followed by incubation with biotin-labeled PAR polymer for 1 h at room temperature in TBS-T buffer.
After washing 3 times in TBS-T buffer, the membranes were blocked with 5% non-fat milk for 1 h, probed using anti-PAR antibody. The bands were visualized by ECL substrate. For PARP-1 in vitro ribosylation assay, 1 mg of recombinant PARP-1, activated DNA and NAD + (Trevigen, Gaithersburg, MD) in the presence or absence of indicated concentration of PARP inhibitors were incubated in the PARP assay buffer (Trevigen) for 30 min at room temperature. For the substrate ribosylation assay of PARP-1, we used 2 or 10 mg of purified a-syn and histone 2B (Abcam) protein under the same condition.
Endosome and exosome enrichment
Endosomes were enriched to detect internalized a-syn-biotin PFF as previously described (5). Primary cultured neurons from WT or PARP-1 KO were incubated with a-syn-biotin PFF for 1.5 h, followed by adding trypsin to remove the membrane-bound a-syn-biotin PFF. After washing with PBS, neurons were harvested and lysed by aspirating a syringe 20 times in lysis buffer [250 mM sucrose, 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 1mM EDTA, 1mM EGTA] with a complete protease inhibitor mixture (Roche). The last pellet containing the endosomes were used for immunoblot analysis after sequential centrifugation at 1000 x g for 10 min, 16,000 x g for 20 min, and 100,000 x g for 60 min at 4°C). Exosomes were enriched to detect secreted a-syn as previously described (18) . Culture supernatants of primary cortical neurons transduced with AAV-a-syn followed by incubation with 500 mM NMDA for 5 min were collected and spun at 300 x g for 10 min to remove cells. The supernatants were then sequentially centrifuged at 2000 × g for 10 min, 10,000 × g for 30 min, and 100,000 × g for 90 min at 4°C). The last pellet containing exosomes was washed once with PBS and centrifuged again at 100,000 × g for 90 min. The remaining pellet was resuspended with lysis buffer.
Cell culture, transfection, primary neuronal culture and treatment SH-SY5Y cells (ATCC, Manassas, VA) were cultured in DMEM containing 10% fetal bovine serum and penicillin/streptomycin at 37°C under 5% CO 2 . The cells were transfected using PolyFect reagent (Qiagen) according to the manufacturer's instructions. Primary cortical neurons from WT or PARP-1 KO embryos were prepared as described previously (28) . Briefly, the primary cortical neurons were cultured at embryonic day 16 in neurobasal media supplemented with B-27, 0.5 mM L-glutamine, penicillin and streptomycin (Invitrogen, Carlsbad, CA). ABT-888 (1 or 10 mM), AG-014699 (1 mM), BMN 673 (1 or 10 mM), Z-VAD (10 mM), Nec-1 (10 mM) or 3-MA (500 mM) were applied to neurons 1 h before a-syn PFF treatment. The neuron culture media was replaced with fresh medium alone or including cell death inhibitors every 3-4 days. a-syn PFF was added at 7 days in vitro (DIV) and further incubated for indicated times followed by the cell death assay or biochemical experiments. Primary neurons were infected with AAV9-control sgRNA or AAV9-PARP-1 sgRNA (ViGene Biosciences, Rockville, MD), and AAVa-syn WT or AAV-a-syn A53T at DIV 4-5.
Cell death and viability assessment
Primary cultured cortical neurons were treated with 5 mg/ml of a-syn PFF or PAR-a-syn PFF for 14 days. Percent of cell death was determined by staining with 7 mM Hoechst 33342 and 2 mM propidium iodide (PI) (Invitrogen). Images were taken and counted by a Zeiss microscope equipped with automated computer assisted software (Axiovision 4.6, Carl Zeiss, Dublin, CA). After adding Alamar Blue (Invitrogen), cell viability was determined by fluorescence at an excitation wavelength 570 nm and an emission wavelength 585 nm (29) .
Microfluidic chambers
Triple compartment microfluidic devices (TCND1000) were obtained from Xona Microfluidic, LLC (Temecula, CA). Glass coverslips were prepared and coated as described, before being affixed to the microfluidic device. Approximately 100,000 WT or PARP-1 KO neurons were plated per chamber individually. At 7 DIV, 5 mg/ml of a-syn PFF was added into chamber 1. To control for direction of flow, a 50 ml difference in media volume was maintained between chamber 1 and chamber 2 and chamber 2 and chamber 3 according to the manufacturers' instructions. Neurons were fixed on day 14 after a-syn PFF treatment using 4% paraformaldehyde in PBS. The chambers were then processed for immunofluorescence staining with a p-a-syn antibody (Table S4) .
Behavioral tests
The behavioral deficits in a-syn PFF injected WT or PARP-1 KO mice, a-syn PFF injected mice fed ABT-888, and a-syn PFF or PAR-a-syn PFF injected mice were assessed by the pole test and the grip strength test 1 week prior to sacrifice of the different cohorts. All the experiments were performed by investigators who were blind to genotypes or treatment condition and randomly allocated to groups.
Pole test
A metal rod (75 cm long with a 9 mm diameter) wrapped with bandage gauze was used as the pole. Before the actual test, the mice were trained for two consecutive days and each training session consisted of three test trials. Mice were placed 7.5 cm from the top of the pole. The time to turn and total time to reach the base of the pole were recorded. The end of test was defined by placement of all 4 paws on the base. The maximum cutoff time to stop the test and recording was 60 s. After each trial, the maze was cleaned with 70% ethanol. In Fig. 3E , we used 4 males and 4 females for WT mice injected with PBS, 4 males and 3 females for WT mice injected with PFF, 3 males and 3 females for PARP-1 KO mice injected with PBS, and 5 males and 2 females for PARP-1 KO mice injected with PFF (Fig. 3E, left) . We used 6 males and 5 females for PBS injected mice fed with chow, 16 males and 9 females for PFF injected mice fed with chow, 6 males and 6 females for PBS injected mice fed with ABT-888, and 15 males and 10 females for PFF injected mice fed with ABT-888 (Fig. 3E, right) . In Fig. 5F , we used 7 males and 7 females for PBS, 8 males and 5 females for PFF, 13 males and 11 females for PAR-PFF, 6 males and 5 females for PARinjected mice at 3 months, and 4 males and 5 females for PBS, 5 males and 5 females for PFF, 7 males and 6 females for PAR-PFF, 5 males and 4 females for PAR-injected mice at 6 months.
Grip strength test
Neuromuscular function was measured by determining the maximal peak force developed by the mice using a grip-strength meter (Bioseb, USA). Mice were placed onto a metal grid to grasp with either fore or both limbs that are recorded as 'fore limb' and 'fore and hindlimb', respectively. The tail was gently pulled and the force applied to the grid before the mice lose their grip was recorded as the peak tension displayed in grams (g). In Fig. 3F , we used 4 males and 3 females for WT mice injected with PBS, 3 males and 3 females for WT mice injected with PFF, 3 males and 3 females for PARP-1 KO mice injected with PBS, and 5 males and 2 females for PARP-1 KO mice injected with PFF (Fig. 3F, left) . We used 10 males and 8 females for PBS injected mice fed with chow, 18 males and 9 females for PFF injected mice fed with chow, 6 males and 6 females for PBS injected mice fed with ABT-888, and 19 males and 11 females for PFF injected mice fed with ABT-888 (Fig. 3F, right) . In Fig. 5G , we used 3 males and 3 females for PBS, 3 males and 3 females for PFF, 3 males and 3 females for PAR-PFF, 3 males and 3 females for PAR-injected mice at 1 months, 4 males and 4 females for PBS, 4 males and 4 females for PFF, 6 males and 5 females for PAR-PFF, 4 males and 4 females for PAR-injected mice at 3 months, and 5 males and 4 females for PBS, 5 males and 5 females for PFF, 8 males and 6 females for PAR-PFF, 5 males and 4 females for PAR-injected mice at 6 months.
Dopamine and derivatives measurement using HPLC
Biogenic amine concentrations were measured by high-performance liquid chromatography with electrochemical detection (HPLC-ECD). The striatum was rapidly removed from the brain, followed by weighing, then sonication in ice cold 0.01 mM of perchloric acid containing 0.01% EDTA. The 60 ng of 3,4-dihydroxybenzylamine (DHBA) was used as an internal standard. After centrifugation at 15,000 g for 30 min at 4°C, the supernatant was cleaned using a 0.2 mm filter and 20 ml of supernatant was analyzed in the HPLC column (3 mm × 150 mm, C-18 reverse phase column, AcclaimTM Polar Advantage II, Thermo Scientific) by a dual channel coulochem III electrochemical detector (Model 5300, ESA, Inc. Chelmsford, MA). The protein concentrations of tissue homogenates were measured using the BCA protein assay kit (Pierce).
Data were normalized to protein concentrations and expressed in ng/mg protein.
Immunohistochemistry and immunofluorescence
Mice were perfused with PBS and 4% PFA and brains were removed, followed by fixation in 4% PFA overnight and transfer to 30% sucrose for cryoprotection. Immunohistochemistry (IHC) and immunofluorescence (IF) was performed on 40 mm thick serial brain sections. Primary antibodies and working dilutions are detailed in Table S4 . For histological studies, free-floating sections were blocked with 10% goat serum in PBS with 0.2% Triton X-100 and incubated with TH or p-a-syn antibodies followed by incubation with biotin-conjugated anti-rabbit or mouse antibody, respectively. After three washes, ABC reagent (Vector laboratories, Burlingame, CA) was added and the sections were developed using SigmaFast DAB peroxidase substrate (SigmaAldrich). Sections were counterstained with Nissl (0.09% thionin). For the quantification, both THand Nissl-positive DA neurons from the SNpc region were counted by an investigator who was blind to genotypes or treatment condition with randomly allocated groups through optical fractionators, the unbiased method for cell counting, using a computer-assisted image analysis system consisting of an Axiophot photomicroscope (Carl Zeiss) equipped with a computer controlled motorized stage (Ludl Electronics, Hawthorne, NY), a Hitachi HV C20 camera, and Stereo Investigator software (MicroBright-Field, Williston, VT). The total number of TH-stained neurons and Nissl counts were analyzed as previously described (16) . For immunofluorescent studies, doublelabeled sections with TH and p-a-syn antibodies were incubated with a mixture of Alexa-fluor 488-and 594-conjugated secondary antibodies (Invitrogen). The fluorescent images were acquired by confocal scanning microscopy (LSM710, Carl Zeiss). All the images were processed by the Zen software (Carl Zeiss). The selected area in the signal intensity range of the threshold was measured using ImageJ software.
Nitric oxide (NO) measurement
NO levels were measured using a NO assay kit (Abcam, Cambridge, MA) according to the manufacturer's instructions. Briefly, the pellets of primary neurons or SNpc tissues were washed with ice-cold PBS, resuspended, and homogenized in ice-cold assay buffer. The supernatant after centrifugation at 16,000 x g for 5 min at 4°C were deproteinized and neutralized (pH 6.5-8) by adding 1M perchloric acid and 2M Potassium Hydroxide. After centrifugation at 13,000 x g for 15 min at 4°C, the supernatant was reacted with nitrate reductase and cofactors at room temperature for 1 h to convert nitrate to nitrite. The amount of the azo compound converted from nitrite by Griess reagents were measured at OD540 nm.
Comet assay
The comet assay was performed according to the manufacturer's instructions (Trevigen). Briefly, primary cortical neurons pre-treated with L-NAME (Sigma-Aldrich) followed by further incubation with a-syn PFF were washed with ice-cold PBS (Ca 2+ and Mg 2+ free), harvested, and resuspended in PBS at 1 x 10 5 cells/ml. After combining with 1% low melting point agarose in PBS at 42°C, 50 ml of the cell-agarose mixture was immediately placed on the Comet slide at 4°C in the dark for 30 min. Slides were lysed in lysis buffer and immersed with alkaline unwinding solution (200 mM NaOH, pH >13, 1 mM EDTA) for 1 hour at room temperature. After electrophoresis at 21 V for 30 min at 4°C, slides were rinsed twice with dH 2 O), fixed with 70% ethanol for 5 min, and then stained with SYBR green for 5 min at 4°C. Images were captured using a Zeiss epifluorescent microscope (Axiovert 200M) and analyzed with the tail positive cells (% of total cells) and tail length (the length from the edge of the nucleus to the end of the comet tail).
Proteinase K (PK) digestion of a-syn PFF PK digestion was performed as previously described (30) . Ten micrograms of a-syn PFF or PAR-a-syn PFF were mixed with 0.5 to 2.5 mg/ml of PK in PBS and incubated at 37°C for 30 min. The reaction was stopped by adding 1 mM PMSF, boiled with SDS-sample buffer for 5 min. The bands of the PK digestion products were detected by immunoblotting using epitope-specific a-syn antibodies (Table S4) .
Human CSF samples and PAR ELISA
Participants at the Johns Hopkins University site of the NINDS Parkinson's Disease Biomarker Program (PDBP) underwent extensive clinical and cognitive testing and a lumbar puncture annually. The CSF was centrifuged, aliquoted, and stored at -80°C within one hour of acquisition. CSF samples were also obtained from the Cleveland Clinic Lou Ruvo Center Brain Health Biobank (CBH-biobank) under similar protocols. Two different clones (#19 and #25) of monoclonal anti-PAR antibody were used for PAR ELISA. Anti-PAR antibody (capture antibody, clone #19) (5 mg/ml) was coated on 96-well microtiter plate (NUNC, Cat #46051), various concentration of purified PAR (0-200 nM, positive control) and CSF samples from either normal or PD patients were added to each well and incubated for 1 h at room temperature (RT). After washing the plates five times with PBST (0.05% Tween20 in PBS buffer), the biotinylated PAR antibody (detection antibody, clone #25) was incubated for 1 h at RT. The color change was detected via HRPconjugated streptavidin antibody (Thermo Scientific). Our assay can detect the PAR as low as 3 pM and is saturated at 50 nM.
Statistical analysis
All data are represented as mean ± s.e.m. with at least 3 independent experiments. Statistical analysis was performed using GraphPad Prism 7. Differences between 2 means and among multiple means were assessed by unpaired two-tailed student t test and ANOVA followed by Tukey's post hoc test, respectively. The distribution of data from human CSF samples were assessed with D'Agostino & Pearson omnibus normality test and non-normally distributed data were analyzed with nonparametric test (Mann-Whitney test). Assessments with P < 0.05 were considered significant.
